

Louisiana Medicaid Pain Management – Cytokine and CAM Antagonists

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request clinical authorization for cytokine or CAM antagonists.

Additional Point-of-Sale edits may apply.

By submitting the authorization request, the prescriber attests to the conditions available [HERE](#).

When currently posted criteria are not met, a clinical reviewer will consider the most current FDA-approved prescribing information for the requested agent when evaluating the request.

General approval criteria for initiation of therapy for both preferred and non-preferred cytokine and CAM antagonists (ALL criteria must be met):

- An appropriate diagnosis is required, and the agent must be prescribed according to U.S. Food and Drug Administration approved indications, dosing, safety and monitoring regulations; AND
- The requested dose does not exceed the quantity limit (if applicable) listed in Table 1; AND
-
- If the request is for a non-preferred agent, there is no preferred alternative that is:
 - The exact same chemical entity, formulation, strength, etc.; **OR**
 - An FDA-approved biosimilar to the requested medication that is indicated for the condition being treated; **AND**
- If the request is for Stelara®, ONE of the following is required:
 - The recipient has a documented treatment failure with an adequate trial (26 weeks) of an FDA-approved biosimilar to Stelara®; OR
 - The provider states on the request clinical justification why EACH biosimilar for Stelara® cannot be used; AND
- For those agents identified as non-preferred on the PDL, the following conditions apply:
 - **ONE** of the following is true and is **stated on the request**
 - The recipient had documented *intolerable side effects* or a documented *treatment failure* with an adequate trial (6-12 weeks) of **TWO** preferred agents, if the preferred agents are indicated for the specified diagnosis; **OR**
 - The recipient has a *contraindication* to the preferred agents indicated for the specified diagnosis.

Approval criteria for initiation of therapy for specific diagnoses:

Acute Graft versus Host Disease, Prophylaxis (Orencia®)

- The recipient is 2 years of age or older; **AND**
- The recipient is undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor; **AND**

- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a hematologist or oncologist; **AND**
- The prescriber **states on the request** that Orencia® will be used in combination with a calcineurin inhibitor (e.g., tacrolimus) and methotrexate.

Alopecia Areata (Litfulo™, Olumiant®)

- For Litfulo™, the recipient is 12 years of age or older; **OR**
- For Olumiant®, the recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The recipient has at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT) for more than 6 months; **AND**
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist or dermatologist; **AND**
 - The agent is not being given in combination with other JAK inhibitors (e.g., tofacitinib), biologic DMARDS, or with potent immunosuppressants such as azathioprine and cyclosporine; **AND**
- For Litfulo™, the recipient has an ALC (absolute lymphocyte count) > 500/mm³ and a platelet count of > 100,000/mm³; **OR**
- For Olumiant®, the recipient has an ANC (absolute neutrophil count) > 1000/mm³, an ALC (absolute lymphocyte count) > 500/mm³, and hemoglobin > 8 g/dL.

Ankylosing Spondylitis [for Bimzelx®, Cimzia®, Cosentyx®, Rinvoq®, and Taltz®, this includes Non-Radiographic Axial Spondyloarthritis] (Abralada™, Amjevita™, Avsola®, Bimzelx®, Cimzia®, Cosentyx®, Cyltezo®, Enbrel®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Inflectra®, Remicade®, Renflexis®, Simlandi®, Simponi®, Simponi Aria®, Taltz®, Xeljanz® tablet, Xeljanz® XR, Yuflyma®, Yusimry™)

- The recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
 - The recipient had documented intolerable side effects or a documented treatment failure with a non-steroidal anti-inflammatory agent (NSAID) during a single 3-month period; **OR**
 - The recipient has a contraindication to NSAIDs; **AND**
 - For Abrilada™, Amjevita™, Cyltezo®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi®, Yuflyma®, or Yusimry™, the quantity does not exceed 2 syringes every 28 days; **OR**
 - For Cosentyx®, the loading dose does not exceed 150mg at Weeks 0, 1, 2, 3, and 4, and the maintenance dose does not exceed 300mg every 28 days thereafter; **OR**
 - For Xeljanz® and Xeljanz® XR:
 - The agent is not being given in combination with biologic DMARDS or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
 - The recipient has an absolute lymphocyte count (ALC) ≥ 500 cells/mm³, an ANC ≥ 1,000 cells/mm³, and hemoglobin level ≥ 9 g/dL; **AND**
 - The recipient has had an inadequate response or intolerance to one or more TNF antagonists; **OR**

- For Rinvoq®:
 - The agent is not being given in combination with JAK inhibitors, biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
 - The recipient has an ALC ≥ 500 cells/mm³, an ANC $\geq 1,000$ cells/mm³, and hemoglobin level ≥ 8 g/dL; **AND**
 - The recipient has had an inadequate response or intolerance to one or more TNF antagonists.

Atopic Dermatitis (Cibinqo™, Rinvoq®)

- The recipient is 12 years of age or older on the date of the request; **AND**
- The following is true and is **stated on the request**:
 - The disease is refractory and moderate to severe; **AND**
 - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6-12 weeks) of **ONE** conventional systemic treatment, including biologics; **AND**
 - There has been a treatment failure or intolerable side effect with or contraindication to a preferred topical corticosteroid agent (see Dermatology – Steroids, Topical – Low, Medium, High and Very High Potency); **AND**
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a dermatologist, immunologist or allergist; **AND**
 - The agent is not being given in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants; **AND**
 - For Cibinqo™:
 - The dose does not exceed 200mg per day; **AND**
 - The recipient has a platelet count $\geq 150,000$ /mm³, an ALC ≥ 500 cells/mm³, an ANC $\geq 1,000$ cells/mm³, and hemoglobin level ≥ 8 g/dL; **OR**
 - For Rinvoq®:
 - The dose does not exceed 30mg per day; **AND**
 - The recipient has an ALC ≥ 500 cells/mm³, an ANC $\geq 1,000$ cells/mm³, and hemoglobin level ≥ 8 g/dL.

Coronavirus Disease 2019 (COVID-19)

- Olumiant®, Actemra®, Tofidence™ and Tyenne® are indicated for the treatment of coronavirus disease 2019 (COVID-19) in **hospitalized adults** and will not be approved for outpatient treatment of COVID-19.

Crohn's Disease (Abrilada™, Amjevita™, Avsola®, Cimzia®, Cyltezo®, Entyvio®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Inflectra®, Omvoh™, Otulfi™, Pyzchiva®, Renflexis®, Remicade®, Rinvoq®, Selarsdi™, Simlandi®, Skyrizi®, Stelara®, Steqeyma®, Tremfya®, Yesintek™, Yuflyma®, Yusimry™, Zymfentra™)

- For Abrilada™, Amjevita™, Avsola®, Cyltezo®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Inflectra®, Renflexis®, Remicade®, Simlandi®, Yuflyma®, or Yusimry™, the recipient is 6 years of age or older; **OR**
- For Cimzia®, Entyvio®, Omvoh™, Otulfi™, Pyzchiva®, Rinvoq®, Selarsdi™, Skyrizi®, Stelara®, Steqeyma®, Tremfya®, Yesintek™, or Zymfentra™ the recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:

- The disease is moderate to severe; **AND**
- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a gastroenterologist; **AND**
- For Abrilada™, Cyltezo®, Hadlima®, Hulio®, Idacio®, Simlandi® or Yusimry™, the quantity does not exceed 6 syringes in the first 28 days of therapy, and 2 syringes every 28 days thereafter; **OR**
- For Amjevita™, Hyrimoz®, or Yuflyma®, the quantity does not exceed 3 syringes in the first 28 days of therapy, and 2 syringes every 28 days thereafter; **OR**
- For Entyvio®, the recipient:
 - Had an inadequate response with, lost response to, or was intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; **OR**
 - Had an inadequate response with, was intolerant to, or demonstrated dependence on corticosteroids; **OR**
- For Otulfi™:
 - The recipient failed or was intolerant to treatment with immunomodulators or corticosteroids, but never failed a TNF blocker; **OR**
 - The recipient failed or was intolerant to treatment with one or more TNF blockers; **AND**
- For Pyzchiva®:
 - The recipient failed or was intolerant to treatment with immunomodulators or corticosteroids, but never failed a TNF blocker; **OR**
 - The recipient failed or was intolerant to treatment with one or more TNF blockers; **AND**
- For Rinvoq®:
 - The agent is not being given in combination with JAK inhibitors, biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
 - The recipient has an ALC ≥ 500 cells/mm³, an ANC $\geq 1,000$ cells/mm³, and hemoglobin level ≥ 8 g/dL; **AND**
 - The recipient has had an inadequate response or intolerance to one or more TNF antagonists; **AND**
 - The following doses are not exceeded:
 - Induction dose of 45mg/day for 12 weeks; **AND**
 - Maintenance dose of 30mg/day; **OR**
- For Selarsdi™:
 - The recipient failed or was intolerant to treatment with immunomodulators or corticosteroids, but never failed a TNF blocker; **OR**
 - The recipient failed or was intolerant to treatment with one or more TNF blockers; **AND**
- For Skyrizi®, the following doses are not exceeded:
 - Induction dose of 600mg IV at Week 0, Week 4, and Week 8; **AND**
 - Maintenance dose of 360mg subcutaneous at Week 12, and every 8 weeks thereafter; **OR**
- For Stelara®, the recipient:
 - Failed or was intolerant to treatment with immunomodulators or corticosteroids, but never failed a TNF blocker; **OR**

- Failed or was intolerant to treatment with one or more TNF blockers;
OR
- For Steqeyma®:
 - The recipient failed or was intolerant to treatment with immunomodulators or corticosteroids, but never failed a TNF blocker; **OR**
 - The recipient failed or was intolerant to treatment with one or more TNF blockers; **AND**
- For Yesintek™, the recipient:
 - Failed or was intolerant to treatment with immunomodulators or corticosteroids, but never failed a TNF blocker; **OR**
 - Failed or was intolerant to treatment with one or more TNF blockers;
OR
- For Zymfentra™, the recipient has completed an intravenous induction regimen with an infliximab product.

Cytokine release syndrome (CRS), severe or life-threatening (Actemra®, Tyenne®)

- The recipient is 2 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The recipient has severe or life-threatening chimeric antigen receptor (CAR) T cell-induced CRS; **AND**
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist or an oncologist or specialist in the area of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome; **AND**
 - Prior to the initiation of treatment, lab testing was performed consisting of a complete blood count (CBC) and liver function test; **AND**
 - Actemra® and Tyenne® are prescribed according to U.S. Food and Drug Administration labeled dosing for CRS:
 - 12mg/kg for recipients weighing < 30kg
 - 8mg/kg for recipients weighing ≥ 30kg;
 - Up to a maximum of 800mg per infusion and a maximum of 4 doses up to at least 8 hours apart.

Deficiency of Interleukin-1 Receptor Antagonist (DIRA) (Arcalyst®, Kineret®)

- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a specialist in the treatment of DIRA; **AND**
- For Arcalyst®:
 - The recipient weighs at least 10kg (current weight is stated on the request); **AND**
 - The maximum weekly dose does not exceed 320mg; **AND/OR**
- For Kineret®, the maximum daily dose does not exceed 8mg/kg.

Enthesitis-Related Arthritis (Cosentyx®)

- The recipient is 4 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**

- The recipient has a contraindication to or documented intolerance or failure with an adequate trial (6-12 weeks) of **AT LEAST ONE** disease modifying antirheumatic drug (DMARD) (such as methotrexate, corticosteroids, or azathioprine); **AND**;
- The dose does not exceed 150mg at Weeks 0, 1, 2, 3, and 4, and every 28 days thereafter.

Generalized Pustular Psoriasis (GPP) Flare (Spevigo®- intravenous dosage form only)

- The recipient is 12 years of age or older and weighs at least 40 kg (recipient weight must be **stated on the request**); **AND**
- The following is true and is **stated on the request**:
 - The recipient has a diagnosis of generalized pustular psoriasis (GPP); **AND**
 - The recipient has had a flare of GPP of moderate-to-severe intensity, as defined by all of the following:
 - A Generalized Pustular Psoriasis Physician Global Assessment (GPPPGA) total score of at least 3 (moderate) [the total GPPPGA score ranges from 0 (clear) to 4 (severe)]; **AND**
 - The presence of fresh pustules (new appearance or worsening of pustules); **AND**
 - GPPPGA pustulation sub-score of at least 2 (mild); **AND**
 - At least 5% of body surface area covered with erythema and the presence of pustules; **AND**
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a dermatologist, immunologist or rheumatologist; **AND**
 - The dose does not exceed 900mg per dose.

Generalized Pustular Psoriasis (GPP) -When Not Experiencing a Flare (Spevigo® - subcutaneous dosage form only)

- The recipient is 12 years of age or older and weighs at least 40 kg (recipient weight must be **stated on the request**); **AND**
- The following is true and is **stated on the request**:
 - The recipient has a diagnosis of generalized pustular psoriasis (GPP); **AND**
 - The recipient has a documented history of at least 2 presentations of moderate to severe GPP flares with fresh pustulation (new appearance or worsening) in the previous 12 months; **AND**
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a dermatologist, immunologist or rheumatologist; **AND**
 - The dose does not exceed 600mg per dose.

Giant Cell Arteritis (Actemra®, Rinvog®, Tofidence™, Tyenne®)

- The recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
 - For Actemra®/Tofidence™/Tyenne®:
 - Prior to the initiation of treatment, lab testing was performed consisting of an ANC, platelet count, and liver function tests (ALT/AST); **AND**

- The recipient has an ANC $\geq 2,000/\text{mm}^3$, a platelet count $\geq 100,000/\text{mm}^3$, and the ALT/AST levels do not exceed 1.5 times the upper limit of normal (ULN);

ORAND

- ~~The recipient had an inadequate response to systemic corticosteroids (e.g., prednisone).~~ For Rinvoq®:

- The dose does not exceed 15mg per day; AND
- The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; AND
- The recipient has an ALC $\geq 500 \text{ cells}/\text{mm}^3$, an ANC $\geq 1,000 \text{ cells}/\text{mm}^3$, and hemoglobin level $\geq 8 \text{ g/dL}$.

Gout Flares (Ilaris®)

- The recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
 - The recipient has experienced at least three gout flares in the previous year; **AND**
 - The recipient has a contraindication to, documented intolerance or treatment failure with **ALL** of the following: colchicine, corticosteroids, and NSAID's; **AND**
 - The recipient is currently being treated with urate-lowering therapy (ULT) (e.g. allopurinol, febuxostat, probenecid) or has a contraindication to all ULT agents; **AND**
 - The maximum dose is 150mg administered subcutaneously as a single dose.

Hidradenitis Suppurativa (Abrilada™, Amjevita™, Bimzelx®, Cosentyx®, Cyltezo®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Simlandi®, Yuflyma®, Yusimry™)

- For Abrilada™, Amjevita™, Bimzelx®, Cosentyx®, Cyltezo®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi®, Yuflyma®, or Yusimry™, the recipient is 18 years of age or older; **AND**
- For Humira®, the recipient is 12 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The recipient has a diagnosis of moderate to severe hidradenitis suppurativa (i.e., Hurley Stage II or III); **AND**
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a dermatologist; **AND**
 - For Bimzelx®, the dose does not exceed 640mg every 28 days for the first 4 months of therapy, and 320mg every 28 days thereafter; OR
 - For Cosentyx®, the loading dose does not exceed 300mg at Weeks 0, 1, 2, 3, and 4, and the maintenance dose does not exceed 300mg every 14 days thereafter; OR
 - For Abrilada™, Cyltezo®, Hadlima®, Hulio®, Idacio®, Simlandi® or Yusimry™, the quantity does not exceed 6 syringes in the first 28 days of therapy, and 4 syringes every 28 days thereafter; **OR**
 - For Amjevita™, Hyrimoz®, or Yuflyma®, the quantity does not exceed 3 syringes in the first 28 days of therapy, and 4 syringes every 28 days thereafter.

Immunoglobulin G4-Related Disease (IgG4-RD) (Uplizna®)

- The recipient is 18 years of age or older; AND

- The following is true and is **stated on the request**:
 - The recipient has a confirmed diagnosis of IgG4-RD; **AND**
 - The recipient has experienced an IgG4-RD flare that required corticosteroid treatment; **AND**
 - The recipient has a confirmed history of IgG4-RD affecting ≥ 2 organs/sites.

Neuromyelitis Optica Spectrum Disorder (NMOSD) (Enspryng®, Uplizna®)

- The recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The recipient has a diagnosis of neuromyelitis optica spectrum disorder; **AND**
 - The recipient is anti-aquaporin-4 (AQP4) antibody positive; **AND**
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a neurologist, ophthalmologist or rheumatologist.

Oral Ulcers Associated with Behçet's Disease (Otezla®)

- The recipient is 18 years of age or older; **AND**
- The recipient has a diagnosis of Behçet's Disease; **AND**
- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
- The request states that the recipient has active oral ulcers.

Periodic Fever Syndromes:

- **Cryopyrin-Associated Periodic Syndromes (CAPS) (Arcalyst®, Kineret®, and Ilaris®)** - The following is true and is **stated on the request**:
 - For Kineret®:
 - The medication is being prescribed for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID), which has been confirmed by one of the following:
 - NLRP-3 [nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]) mutation; **OR**
 - Evidence of active inflammation which includes both clinical symptoms (e.g., rash, fever, arthralgia) and elevated acute phase reactants (e.g., ESR, CRP); **AND**
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist or a specialist in the treatment of NOMID; **AND**
 - The maximum daily dose does not exceed 8mg/kg; **OR**
 - For Arcalyst® and Ilaris®:
 - The medication is being prescribed for the treatment of either Familial Cold Autoinflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS); **AND**
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist or a specialist in the treatment of FCAS and MWS; **AND**
 - For Arcalyst®:

- The recipient is 12 years of age or older; **OR**
 - For Ilaris®:
 - The recipient is 4 years of age or older; **AND**
 - The maximum dose is 150mg every 8 weeks.
- **Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS); OR Hyperimmunoglobulin D Syndrome (HIDS); OR Mevalonate Kinase Deficiency (MKD); OR Familial Mediterranean Fever (FMF) (Ilaris®)**
 - The recipient is 2 years of age or older; **AND**
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist or a specialist in the treatment of TRAPS, HIDS, MKD and FMF; **AND**
 - The maximum dose is 300mg every 4 weeks.

Plaque Psoriasis (Abralada™, Amjevita™, Avsola®, Bimzelx®, Cimzia®, Cosentyx®, Cyltezo®, Enbrel®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Ilumya®, Inflectra®, Otezla®, Otulfi™, Pyzchiva®, Remicade®, Renflexis®, Selarsdi™, Siliq®, Simlandi®, Skyrizi®, Sotyktu™, Stelara®, Steqeyma®, Taltz®, Tremfya®, Yesintek™, Yuflyma®, Yusimry™)

- For Abrilada™, Amjevita™, Avsola®, Bimzelx®, Cimzia®, Cyltezo®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Ilumya®, Inflectra®, Remicade®, Renflexis®, Siliq®, Simlandi®, Skyrizi®, Sotyktu™, Tremfya®, Yuflyma®, or Yusimry™, the recipient is 18 years of age or older; **OR**
- For Cosentyx®, Otulfi™, Pyzchiva®, Selarsdi™, Stelara®, Steqeyma®, Taltz®, or Yesintek™, the recipient is 6 years of age or older; **OR**
- For Enbrel®, the recipient is 4 years of age or older; **OR**
- For Otezla®, the recipient is 6 years of age or older and weighs at least 20 kg (recipient weight must be **stated on the request**); **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist or dermatologist; **AND**
 - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6-12 weeks) of **AT LEAST ONE** of the following therapies: phototherapy, methotrexate, and/or cyclosporine; **AND**
 - For all agents except Otezla® when used in recipients 18 years of age or older, the recipient has Body Surface Area (BSA) involvement of at least 3% or involvement of the palms, soles, head and neck or genitalia, causing disruption in normal activities and/or employment; **AND**
 - For Abrilada™, Cyltezo®, Hadlima®, Hulio®, Idacio®, Simlandi® or Yusimry™, the quantity does not exceed 4 syringes in the first 28 days of therapy, and 2 syringes every 28 days thereafter; **OR**
 - For Cosentyx®, the loading dose does not exceed 300mg at Weeks 0, 1, 2, 3, and 4, and the maintenance dose does not exceed 300mg every 28 days thereafter; OR
 - For Skyrizi®, the dose does not exceed 150mg at Week 0, Week 4 and every 12 weeks thereafter; **OR**

- For Amjevita™, Hyrimoz®, or Yuflyma®, the quantity does not exceed 3 syringes in the first 28 days of therapy, and 2 syringes every 28 days thereafter; **OR**
- For Sotyktu™:
 - The dose does not exceed 6mg per day; **AND**
 - The agent is not being given in combination with potent immunosuppressants such as azathioprine and cyclosporine; **OR**
- For Abrilada™, Amjevita™, Cimzia®, Cosentyx®, Cyltezo®, Enbrel®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Otulfi™, Pyzchiva®, Selarsdi™, Siliq®, Simlandi®, Stelara®, Steqeyma®, Taltz®, Tremfya®, Yesintek™, Yuflyma®, or Yusimry™, the disease is chronic moderate to severe plaque psoriasis; **OR**
- For Bimzelx®, Ilumya®, Skyrizi® or Sotyktu™, the recipient has a diagnosis of moderate-to-severe plaque psoriasis; **OR**
- For Avsola®, Inflectra®, Remicade® or Renflexis®, the disease is chronic severe plaque psoriasis; **OR**
- For Otezla® when used in recipients 6-17 years of age, the disease is moderate-to-severe plaque psoriasis; **OR**
- For Siliq®, the following criteria must be met:
 - The recipient has tried at least one traditional systemic agent for psoriasis (e.g., methotrexate, cyclosporine, acitretin tablets, or psoralen plus ultraviolet A light) for at least 3 months, (unless intolerant); **OR**
 - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (3 months) of a non-biologic agent indicated for psoriasis; **AND**
 - By submitting the authorization request, the prescriber attests to the following:
 - The recipient does not have Crohn's Disease; **AND**
 - The recipient has signed the Siliq® recipient-prescriber agreement form; **AND**
 - All approval criteria for the REMS (Risk Evaluation and Mitigation Strategy) program have been met.

Polyarticular Juvenile Idiopathic Arthritis (Abrilada™, Actemra®, Amjevita™, Cimzia®, Cyltezo®, Enbrel®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Kevzara®, Orencia®, Rinvoq®/Rinvoq® LQ, Simlandi®, Simponi Aria®, Tofidence™, Tyenne®, Xeljanz® tablet, Xeljanz® oral solution, Yuflyma®, Yusimry™)

- The recipient is 2 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
 - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6-12 weeks) of methotrexate or corticosteroids; **AND**
 - For Abrilada™, Amjevita™, Cyltezo®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi®, Yuflyma®, or Yusimry™, the quantity does not exceed 2 syringes every 28 days; **OR**
 - For Kevzara®:
 - The recipient weighs 63kg or greater; **AND**

- The recipient has an ANC $\geq 2000/\text{mm}^3$, a platelet count $\geq 150,000/\text{mm}^3$ and liver transaminases do not exceed 1.5 times the upper limit of normal (ULN); **OR**
- For Rinvoq®/Rinvoq® LQ:
 - The dose does not exceed 15mg per day; **AND**
 - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
 - The recipient has an ALC ≥ 500 cells/ mm^3 , an ANC $\geq 1,000$ cells/ mm^3 , and hemoglobin level ≥ 8 g/dL; **AND**
 - The recipient has had an inadequate response or intolerance to one or more TNF antagonists; **OR**
- For Xeljanz® tablet and Xeljanz® oral solution:
 - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
 - The recipient has an absolute lymphocyte count (ALC) ≥ 500 cells/ mm^3 , an ANC $\geq 1,000$ cells/ mm^3 , and hemoglobin level ≥ 9 g/dL; **AND**
 - The recipient has had an inadequate response or intolerance to one or more TNF antagonists.

Polymyalgia Rheumatica (PMR) (Kevzara®)

- The recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
 - The recipient has an ANC $\geq 2000/\text{mm}^3$, a platelet count $\geq 150,000/\text{mm}^3$ and liver transaminases do not exceed 1.5 times the upper limit of normal (ULN); **AND**
 - The recipient has a contraindication to, documented intolerance or treatment failure with a trial of corticosteroids **OR** is established on corticosteroid therapy and cannot tolerate corticosteroid taper.

Psoriatic Arthritis (Abrilada™, Amjevita™, Avsola®, Bimzelx®, Cimzia®, Cosentyx®, Cyltezo®, Enbrel®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Inflectra®, Orencia®, Otezla®, Otulfi™, Pyzchiva®, Remicade®, Renflexis®, Rinvoq®/Rinvoq® LQ, Selarsdi™, Simlandi®, Simponi®, Simponi Aria®, Skyrizi®, Stelara®, Steqeyma®, Taltz®, Tremfya®, Xeljanz® tablet, Xeljanz® XR, Yesintek™, Yuflyma®, Yusimry™)

- For Abrilada™, Amjevita™, Avsola®, Bimzelx®, Cimzia®, Cyltezo®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Inflectra®, Otezla®, Remicade®, Renflexis®, Simlandi®, Simponi®, Skyrizi®, Taltz®, Tremfya®, Xeljanz® tablet, Xeljanz® XR, Yuflyma®, or Yusimry™, the recipient is 18 years of age or older; **OR**
- For Otulfi™, Pyzchiva®, Selarsdi™, Stelara®, Steqeyma® or Yesintek™, the recipient is 6 years of age or older; **OR**
- For Cosentyx®, Enbrel®, Orencia®, Rinvoq®/Rinvoq® LQ, or Simponi Aria®, the recipient is 2 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a dermatologist or rheumatologist; **AND**

- For Abrilada™, Amjevita™, Cyltezo®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi®, Yuflyma®, or Yusimry™, the quantity does not exceed 2 syringes every 28 days; **OR**
- For Cosentyx®, the loading dose does not exceed 150mg at Weeks 0, 1, 2, 3, and 4, and the maintenance dose does not exceed 300mg every 28 days thereafter; **OR**
- For Rinvoq®/Rinvoq® LQ:
 - The dose does not exceed 15mg per day; **AND**
 - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
 - The recipient has an ALC ≥ 500 cells/mm³, an ANC $\geq 1,000$ cells/mm³, and hemoglobin level ≥ 8 g/dL; **AND**
 - The recipient has had an inadequate response or intolerance to one or more TNF antagonists; **OR**
- For Skyrizi®, the dose does not exceed 150mg at Week 0, Week 4 and every 12 weeks thereafter; **OR**
- For Xeljanz® and Xeljanz® XR:
 - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
 - The recipient has an absolute lymphocyte count (ALC) ≥ 500 cells/mm³, an ANC $\geq 1,000$ cells/mm³, and hemoglobin level ≥ 9 g/dL; **AND**
 - The recipient has had an inadequate response or intolerance to one or more TNF antagonists.

Recurrent Pericarditis (Arcalyst®)

- The recipient is 12 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a cardiologist; **AND**
 - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial of at least one standard of care therapy (such as NSAIDs and colchicine).

Rheumatoid Arthritis (Abrilada™, Actemra®, Amjevita™, Avsola®, Cimzia®, Cyltezo®, Enbrel®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Inflectra®, Kevzara®, Kineret®, Olumiant®, Orencia®, Remicade®, Renflexis®, Rinvoq®, Simlandi®, Simponi®, Simponi Aria®, Tofidence™, Tyenne®, Xeljanz® tablet, Xeljanz® XR, Yuflyma®, Yusimry™)

- The recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
 - The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6-12 weeks) of at least one non-biologic DMARD (such as methotrexate, leflunomide, or azathioprine); **AND**
 - The agent is being used to treat moderately to severely active rheumatoid arthritis; **AND**

- For Abrilada™, Amjevita™, Cyltezo®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi®, Yuflyma®, or Yusimry™, the quantity does not exceed 4 syringes every 28 days; **OR**
- For Actemra®, the dose does not exceed 800mg per infusion; **OR**
- For Rinvoq®:
 - The dose does not exceed 15mg per day; **AND**
 - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
 - The recipient has an ALC ≥ 500 cells/mm³, an ANC $\geq 1,000$ cells/mm³, and hemoglobin level ≥ 8 g/dL; **AND**
 - ~~The recipient has a contraindication to, documented intolerance or treatment failure with an adequate trial (6–12 weeks) of methotrexate; **AND**~~
 - The recipient has had an inadequate response or intolerance to one or more TNF antagonists; **OR**
- For Xeljanz® tablet and Xeljanz® XR:
 - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
 - The recipient has an ALC ≥ 500 cells/mm³, an ANC $\geq 1,000$ cells/mm³, and hemoglobin level ≥ 9 g/dL; **AND**
 - The recipient has had an inadequate response or intolerance to one or more TNF antagonists; **OR**
- For Avsola®, Inflectra®, Remicade®, Renflexis®, Simponi®, or Simponi® Aria, the medication is being used in combination with methotrexate; **OR**
- For Kevzara®, the recipient has an ANC ≥ 2000 /mm³, a platelet count $\geq 150,000$ /mm³ and liver transaminases do not exceed 1.5 times the upper limit of normal (ULN); **OR**
- For Olumiant®:
 - The recipient has had an inadequate response to one or more TNF antagonists; **AND**
 - The agent is not being given in combination with other JAK inhibitors (e.g., tofacitinib), biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine; **AND**
 - The recipient has an ANC ≥ 1000 /mm³, an ALC ≥ 500 /mm³, and hemoglobin ≥ 8 g/dL.

Still's Disease (Ilaris®) [Including Adult-Onset Still's Disease]

- The recipient is 2 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a pulmonologist or rheumatologist; **AND**
 - The maximum dose is 300mg every 4 weeks administered subcutaneously; **AND**
 - The recipient has a contraindication to or documented intolerance or failure with an adequate trial (6-12 weeks) of **AT LEAST ONE** disease modifying antirheumatic drug (DMARD) (such as methotrexate, corticosteroids, or azathioprine).

Systemic Juvenile Idiopathic Arthritis (Actemra®, Ilaris®, Tofidence™, Tyenne®)

- The recipient is 2 years of age or older; **AND**
- The following is true and is **stated on the request**:

- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a rheumatologist; **AND**
- For Ilaris®, the maximum dose is 300mg every 4 weeks administered subcutaneously; **AND**
- The recipient has a contraindication to or documented intolerance or failure with an adequate trial (6-12 weeks) of **AT LEAST ONE** disease modifying antirheumatic drug (DMARD) (such as methotrexate, corticosteroids, or azathioprine).

Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) (Actemra®)

- The recipient is 18 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a pulmonologist; **AND**
 - The maximum dose is 162mg given subcutaneously once a week.

Ulcerative Colitis (Abrilada™, Amjevita™, Avsola®, Cyltezo®, Entyvio®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Inflectra®, Omvoh™, Otulfi™, Pyzchiva®, Remicade®, Renflexis®, Rinvoq®, Selarsdi™, Simlandi®, Simponi®, Skyrizi®, Stelara®, Steqeyma®, Tremfya®, Velsipity™, Xeljanz® Tablet, Xeljanz® XR, Yesintek™, Yuflyma®, Yusimry™, Zymfentra™)

- For Abrilada™, Amjevita™, Cyltezo®, Entyvio®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Omvoh™, Otulfi™, Pyzchiva®, Rinvoq®, Selarsdi™, Simlandi®, Simponi®, Skyrizi®, Stelara®, Steqeyma®, Tremfya®, Velsipity™, Xeljanz® tablet, Xeljanz® XR, Yesintek™, Yuflyma®, Yusimry™, or Zymfentra™, the recipient is 18 years of age or older; **OR**
- For Avsola®, Inflectra®, Remicade® or Renflexis®, the recipient is 6 years of age or older; **OR**
- For Humira®, the recipient is 5 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The disease is moderate to severe; **AND**
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a gastroenterologist; **AND**
 - For Entyvio®, the recipient had an inadequate response with, lost response to, or was intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, was intolerant to, or demonstrated dependence on corticosteroids; **OR**
 - For Abrilada™, Cyltezo®, Hadlima®, Hulio®, Idacio®, Simlandi® or Yusimry™, the quantity does not exceed 6 syringes in the first 28 days of therapy, and 2 syringes every 28 days thereafter; **OR**
 - For Amjevita™, Hyrimoz®, or Yuflyma®, the quantity does not exceed 3 syringes in the first 28 days of therapy, and 2 syringes every 28 days thereafter; **OR**
 - For Rinvoq®:
 - The agent is not being given in combination with JAK inhibitors, biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
 - The recipient has an ALC ≥ 500 cells/mm³, an ANC $\geq 1,000$ cells/mm³, and hemoglobin level ≥ 8 g/dL; **AND**

- The recipient has had an inadequate response or intolerance to one or more TNF antagonists; **OR**
- For Simponi®, the following doses are not exceeded:
 - Induction dose of 200mg at Week 0 followed by 100mg at Week 2; AND
 - Maintenance dose of 100mg every 4 weeks; OR
- For Skyrizi®, the following doses are not exceeded:
 - Induction dose of 1200mg IV at Week 0, Week 4, and Week 8; **AND**
 - Maintenance dose of 360mg subcutaneous at Week 12, and every 8 weeks thereafter; **OR**
- For Xeljanz® tablet and Xeljanz® XR:
 - The agent is not being given in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine; **AND**
 - The recipient has an ALC ≥ 500 cells/mm³, an ANC $\geq 1,000$ cells/mm³, and hemoglobin level ≥ 9 g/dL; **AND**
 - The recipient has had an inadequate response or intolerance to one or more TNF antagonists; **OR**
- For Zymfentra™, the recipient has completed an intravenous induction regimen with an infliximab product.

Uveitis (Abrilada™, Amjevita™, Cyltezo®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Simlandi®, Yuflyma®, Yusimry™)

- The recipient has a diagnosis of non-infectious intermediate, posterior, and panuveitis; **AND**
- For Abrilada™, Amjevita™, Cyltezo®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi®, Yuflyma®, or Yusimry™, the recipient is 18 years of age or older; **OR**
- For Humira®, the recipient is 2 years of age or older; **AND**
- The following is true and is **stated on the request**:
 - The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, an ophthalmologist or a rheumatologist; **AND**
 - The recipient had an inadequate response to conventional treatment for uveitis, which may include corticosteroids; **AND**
 - For Abrilada™, Cyltezo®, Hadlima®, Hulio®, Idacio®, Simlandi® or Yusimry™, the quantity does not exceed 4 syringes in the first 28 days of therapy, and 2 syringes every 28 days thereafter; **OR**
 - For Amjevita™, Hyrimoz®, or Yuflyma®, the quantity does not exceed 3 syringes in the first 28 days of therapy, and 2 syringes every 28 days thereafter.

Approval criteria for continuation of therapy for both preferred and non-preferred cytokine or CAM antagonists (Except for Orencia® when used for prophylaxis of acute graft vs host disease AND Spevigo®):

- The prescriber **states on the request** that there is evidence of a positive response to treatment as indicated by improvement in signs and symptoms compared to baseline, or by halting of disease progression (no progression of disease signs and symptoms as compared to baseline); **AND**
- The requested dose does not exceed the quantity limit (if applicable) listed in Table 1; AND

- For Abrilada™, Amjevita™, Cyltezo®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Simlandi®, Yuflyma®, or Yusimry™, if diagnosis is ulcerative colitis, the prescriber **states on the request** that there is evidence of clinical remission.

Duration of approval for initiation of therapy:

- Abrilada™, Amjevita™, Cyltezo®, Hadlima®, Hulio®, Humira®, Hyrimoz®, Idacio®, Simlandi®, Yuflyma®, or Yusimry™ for ulcerative colitis: 8 weeks
- Ilaris® for gout flares: 3 days (to allow for 1 dose) – Subsequent authorization of Ilaris® for additional gout flares will require meeting the initial approval criteria **AND** a minimum of 12 weeks since last dose of Ilaris®.
- Orencia® for prophylaxis of acute graft vs host disease: 28 days per transplantation
- Spevigo® (intravenous dosage form only) duration of approval: 10 days (to allow for up to 2 doses) – Subsequent authorization of Spevigo® (intravenous dosage form only) for additional GPP flares will require meeting the initial approval criteria **AND** documented resolution of the previous GPP flare.
- Duration of approval for initiation of all other agents / conditions: 6 months

Duration of approval for continuation of therapy: 12 months

Table 1. Quantity Limits for Selected Cytokine/CAM Antagonists	
Generic (Brand Example)	Quantity Limit
<u>Abatacept Clickject, Syringe (Orencia®)</u>	<u>4 injections per 28 days</u>
<u>Abrocitinib Tablet (Cibinqo™)</u>	<u>30 tablets per 30 days; Maximum 1 tablet per day</u>
<u>Adalimumab Pen Kit, Syringe Kit (Humira®)</u> <u>10mg, 20mg, 40mg</u>	<u>4 injections per 28 days</u>
<u>Adalimumab Pen Kit (Humira®) 80mg</u>	<u>2 injections per 28 days</u>
<u>Adalimumab Biosimilars</u>	<u>See diagnosis-specific criteria</u>
<u>Anakinra Syringe (Kineret®)</u>	<u>30 injections per 30 days</u>
<u>Apremilast Tablet (Otezla®)</u>	<u>60 tablets per 30 days; Maximum 2 tablets per day</u>
	<u>Starter Pack - 1 fill per 365 days</u>
<u>Baricitinib Tablet (Olumiant®)</u>	<u>30 tablets per 30 days; Maximum 1 tablet per day</u>
<u>Bimekizumab-bkzx Pen, Syringe (Bimzelx®)</u>	<u>1 injection per 28 days</u> <u>(see diagnosis-specific criteria for HS loading dose)</u>
<u>Brodalumab Syringe (Siliq®)</u>	<u>Starting Dose – 3 injections per 28 days</u>
	<u>Maintenance Dose – 2 injections per 28 days</u>
<u>Canakinumab/PF Vial (Ilaris®)</u>	<u>2 vials per 28 days</u>
<u>Certolizumab Pegol Syringe Kit (Cimzia®)</u>	<u>Syringes – 2 injections per 28 days</u>
	<u>Starter Kit - 1 fill per 365 days</u>
<u>Deucravacitinib Tablet (Sotyktu®)</u>	<u>30 tablets per 30 days; Maximum 1 tablet per day</u>
<u>Etanercept Cartridge, Pen, Syringe, Vial</u> <u>(Enbrel®)</u>	<u>Starting Dose – 8 injections per 28 days for 3 months (if</u> <u>applicable)</u>

	<u>Maintenance Dose – 4 injections per 28 days</u>
<u>Etrasimod Tablet (Velsipity™)</u>	<u>30 tablets per 30 days; Maximum 1 tablet per day</u>
<u>Golimumab Pen, Syringe (Simponi®)</u>	<u>1 injection per 28 days</u> <u>(see diagnosis specific criteria for UC loading dose)</u>
<u>Guselkumab Autoinjector, Pen, Syringe (Tremfya®)</u>	<u>100mg/ml (starting dose) – 1 injection per 28 days for 2 months</u>
	<u>100mg/ml (maintenance dose) – 1 injection per 56 days</u>
	<u>200mg/2ml Starter Kit – 1 fill per 365 days</u>
	<u>200mg/2ml – 1 injection per 28 days</u>
<u>Infliximab-dyyb Pen, Syringe (Zymfentra™)</u>	<u>2 injections per 28 days</u>
<u>Ixekizumab Autoinjector, Syringe (Taltz®)</u>	<u>3-pack – 1 fill per 365 days</u>
	<u>2-pack – 2 fills per 365 days</u>
	<u>1 injection per 28 days</u>
<u>Mirkizumab-mrkz Pen, Syringe (Omvo™)</u>	<u>2 injections per 28 days</u>
<u>Rilonacept Vial (Arcalyst®)</u>	<u>Starting Dose – 5 vials per 28 days for 1 month</u>
	<u>Maintenance Dose – 4 vials per 28 days</u>
<u>Risankizumab-rzaa On-Body Cartridge, Pen, Syringe, Vial (Skyrizi®)</u>	<u>Cartridge – 1 cartridge per 56 days</u>
	<u>Syringe/Pen (starting dose) – 1 injection per 28 days for 2 months</u>
	<u>Syringe/Pen (maintenance dose) – 1 injection per 84 days</u>
	<u>Vial – see diagnosis-specific criteria</u>
<u>Ritlecitinib Tablet (Litfulo™)</u>	<u>30 tablets per 30 days; Maximum 1 tablet per day</u>
<u>Sarilumab Pen, Syringe (Kevzara®)</u>	<u>2 injections per 28 days</u>
<u>Satralizumab-mwge Syringe (Enspryng™)</u>	<u>Starting Dose – 2 injections per 28 days for one month</u>
	<u>Maintenance Dose – 1 injection per 28 days</u>
<u>Secukinumab Pen, Syringe (Cosentyx®)</u>	<u>See diagnosis-specific criteria</u>
<u>Tildrakizumab-asmn Syringe (Ilumya®)</u>	<u>Starting Dose – 1 injection per 28 days for 2 months</u>
	<u>Maintenance Dose – 1 injection per 84 days</u>
<u>Tocilizumab Pen, Syringe (Actemra®)</u> <u>Tocilizumab-aazg Pen, Syringe (Tyenne®)</u> <u>Tocilizumab-bavi Pen, Syringe (Tofidence™)</u>	<u>4 injections per 28 days</u>
<u>Tofacitinib Citrate Tablet, Solution (Xeljanz®)</u> <u>Tofacitinib Citrate ER Tablet (Xeljanz® XR)</u>	<u>Tablet – 60 tablets per 30 days; Maximum 2 tablets per day</u>
	<u>XR Tablet – 30 tablets per 30 days; Maximum 1 tablet per day</u>
	<u>Solution – 300mls per 30 days; Maximum 10mls per day</u>
<u>Upadacitinib ER Tablet (Rinvoq™)</u> <u>Upadacitinib Solution (Rinvoq™ LQ)</u>	<u>Tablet – 30 tablets per 30 days; Maximum 1 tablet per day</u>
	<u>Solution – 360mls per 30 days; Maximum 12mls per day</u>
<u>Ustekinumab Syringe, Vial (Stelara®)</u>	<u>Syringe (starting dose) – 1 injection per 28 days for 2 months</u>

Ustekinumab-aauz Syringe, Vial (Otulfi™)	Syringe (maintenance dose) – 1 injection per 56 days
Ustekinumab-aekn Syringe, Vial (Selarsdi™)	
Ustekinumab-kfce Syringe, Vial (Yesintek™)	Vial – 4 vials (as 56-day supply) per 365 days
Ustekinumab-stba Syringe, Vial (Steqeyma™)	
Ustekinumab-ttwe Syringe, Vial (Pyzchiva™)	
Vedolizumab Pen, Vial (Entyvio®)	Pen – 2 injections per 28 days
	Vial (starting dose) – 2 vials per 28 days for one month
	Vial (maintenance dose) – 1 vial per 56 days

References

Abrilada (adalimumab-afzb) [package insert]. New York, NY: Pfizer Inc; January 2024.
<https://labeling.pfizer.com/ShowLabeling.aspx?id=12780>

Actemra (tocilizumab) [package insert]. South San Francisco, CA: Genentech, Inc; December 2022. https://www.gene.com/download/pdf/actemra_prescribing.pdf

Alikhan A, et al. (2019). North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management. *Journal of the American Academy of Dermatology*, 81(1), 91-101.
<https://doi.org/10.1016/j.jaad.2019.02.068>

Amjevita (adalimumab-atto) [package insert]. Thousand Oaks, CA: Amgen Inc; August 2023.
https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Amjevita/amjevita_pi_hcp_english.pdf

Arcalyst (rilonacept) [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; May 2021. https://www.arcalyst.com/sites/arcalyst.com/files/2021-08/PI_IFU.pdf

Avsola (infliximab-axxq) [package insert]. Thousand Oaks, CA: Amgen Inc; September 2021. https://www.pi.amgen.com/~/-/media/amgen/repositorysites/pi-amgen-com/avsola/avsola_pi_english.ashx

Bimzelx (bimekizumab-bkzx) [package insert]. Smyrna, GA: UCB, Inc; November 2024.
<https://www.ucb-usa.com/bimzelx-prescribing-information.pdf>

Chiabrando, JG, et al. (2020). Management of Acute and Recurrent Pericarditis. *Journal of the American College of Cardiology*, 75(1), 76-92.
<https://doi.org/10.1016/j.jacc.2019.11.021>

Cibinqo (abrocitinib) [package insert]. New York, NY: Pfizer Inc; February 2023.
labeling.pfizer.com/ShowLabeling.aspx?id=16652

Cimzia (certolizumab pegol) [package insert]. Smyrna, GA: UCB, Inc; September 2024.
[CIMZIA_full_prescribing_information.pdf](https://www.cimzia.com/CIMZIA_full_prescribing_information.pdf)

[ClinicalTrials.gov. A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease.](https://clinicaltrials.gov/study/NCT04540497)
<https://clinicaltrials.gov/study/NCT04540497>

Cosentyx (secukinumab) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; October 2023. https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf

Cryopyrin-associated periodic syndromes: MedlinePlus Genetics. (n.d.).
<https://ghr.nlm.nih.gov/condition/neonatal-onset-multisystem-inflammatory-disease#sourcesforpage>

Cyltezo (adalimumab-adbm) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; June 2023. <https://content.boehringer-ingelheim.com/DAM/9d0e3bae-9a17-4979-91bc-af1e011eeb8a/cyltezo-us-pi.pdf>

Donahue, K, et al. (2018). *Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update.* <https://doi.org/10.23970/ahrqepccer211>

Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Immunex Corporation; June 2022. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/enbrel/enbrel_pi.pdf

Enspryng (satralizumab-mwge) [package insert]. South San Francisco, CA: Genentech, Inc; March 2022. https://www.gene.com/download/pdf/enspryng_prescribing.pdf

Entyvio (vedolizumab) [package insert]. Deerfield, IL: Takeda Pharmaceuticals; June 2022. content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1

FitzGerald, J, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. *American College of Rheumatology*, Vol. 72, No. 6, June 2020, pp 744–760. DOI 10.1002/acr.24180

Gottlieb, A, et al. (2008). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. *Journal of the American Academy of Dermatology*, (58)5, 851-864. <https://doi.org/10.1016/j.jaad.2008.02.040>

Hadlima (adalimumab-bwwd) [package insert]. Jersey City, NJ: Organon LLC; July 2023. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4774a951-3ce8-43b6-80b1-e6b23752aae6&type=display>

Hahn, Y. (2018). Enthesitis-related Arthritis. *Journal of Rheumatic Disease*, 25(4), 221. <https://doi.org/10.4078/jrd.2018.25.4.221>

Hulio (adalimumab-fkjp) [package insert]. Morgantown, WV: Mylan Specialty L.P.; December 2023. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=661ad70b-c313-2899-8a7e-7a67bd897ca9&type=display>

Humira (adalimumab) [package insert]. North Chicago, IL: AbbVie Inc; February 2024. <https://www.rxabbvie.com/pdf/humira.pdf>

Hyrimoz (adalimumab-adaz) [package insert]. Princeton, NJ: Sandoz Inc; September 2023.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761071s0161bl.pdf

Idacio (adalimumab-aacf) [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; October 2023. <https://www.idaciohcp.com/downloads/Idacio-PI-vJuly2023.pdf>

Ilaris (canakinumab) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; August 2023. <https://www.novartis.us/sites/www.novartis.us/files/ilaris.pdf>

Ilumya (tildrakizumab-asmn) [package insert]. , Cranbury, NJ: Sun Pharmaceutical Industries; December 2022. https://www.ilumyapro.com/content/dam/ilumya-pro/Sun-Pharma_ILUMYA_US_Prescribing-Info-and-Medication-Guide_combined.pdf

Inflectra (infliximab-dyyb) [package insert]. New York, NY: Pfizer Labs; April 2023. <https://labeling.pfizer.com/ShowLabeling.aspx?id=9271>

Jamilloux Y, et al. (2014). Treatment of Adult-onset Still's Disease: A Review. *Therapeutics and Clinical Risk Management*, 33. <https://doi.org/10.2147/tcrm.s64951>

Kevzara (sarilumab) [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; June 2024. [Kevzara.pdf \(sanofi.us\)](#)

Kineret (anakinra) [package insert]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; December 2020. [Full-Prescribing-Information-English.pdf \(kineretrhcp.com\)](#)

Litfulo (ritlecitinib) [package insert]. New York, NY: Pfizer Labs; June 2023. <https://labeling.pfizer.com/ShowLabeling.aspx?id=19638>

Megna M, Napolitano M, Patruno C, et al. (2016). Systemic Treatment of Adult Atopic Dermatitis: A Review. *Dermatology and Therapy*, 7(1), 1-23. <https://doi.org/10.1007/s13555-016-0170-1>

Olumiant (baricitinib) [package insert]. Indianapolis, IN: Lilly USA, LLC; June 2022. <https://uspl.lilly.com/olumiant/olumiant.html#pi>

OmvoH (mirikizumab-mrkz) [package insert]. Indianapolis, IN: Eli Lilly and Company; January 2025. <https://pi.lilly.com/us/omvoh-uspi.pdf>

Orencia (abatacept) [package insert]. Princeton, NJ: Bristol-Myers Squibb; October 2023. [ORENCIA U.S. Prescribing Information \(bms.com\)](#)

Otezla (apremilast) [package insert]. Summit, NJ: Celgene Corporation; April 2024. https://www.pi.amgen.com/~media/amgen/repositorysites/pi-amgen-com/otezla/otezla_pi_english.ashx

Otulf (ustekinumab-aaaz) [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; September 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761379s0011bl.pdf

Pyzchiva (ustekinumab- ttwe) [package insert]. Princeton, NJ: Sandoz Inc; June 2024. <https://us-sandoz->

com.cms.sandoz.com/sites/default/files/Media%20Documents/BLA%20761373%20and%20BLA%20761425%20PI%20MG%20and%20IFU.pdf

Remicade (infliximab) [package insert]. Horsham, PA: Janssen Biotech; October 2021. <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/REMICADE-pi.pdf>

Renflexis (infliximab-abda) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; December 2023. https://www.organon.com/product/usa/pi_circulars/r/renflexis/renflexis-pi.pdf

Rinvoq (upadacitinib) [package insert]. North Chicago, IL: AbbVie Inc; April 202⁵⁴. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf
https://www.rxabbvie.com/pdf/rinvoq_pi.pdf

Selarsdi (ustekinumab-aekn) [package insert]. Parsippany, NJ: Teva Pharmaceuticals; February 2025. <https://www.selarsdi.com/globalassets/selarsdi/prescribing-information.pdf>

Siliq (brodalumab) [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals; April 2020. <https://pi.bauschhealth.com/globalassets/BHC/PI/Siliq-pi.pdf>

Simlandi (adalimumab-ryvk) [package insert]. Parsippany, NJ: Teva Pharmaceuticals; June 2024. <https://www.simlandihcp.com/globalassets/simlandi/prescribing-information.pdf>

Simponi (golimumab) [package insert]. Horsham, PA: Janssen Biotech; September 2019. [SIMPONI-pi.pdf \(janssenlabels.com\)](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI-pi.pdf)

Simponi Aria (golimumab) [package insert]. Horsham, PA: Janssen Biotech; February 2021. <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI+ARIA-pi.pdf>

Singh J, et al. (2015). 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care and Research*, 68(1), 1-25. <https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.22783>

Singh J, et al. (2018). 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis & Rheumatology*, 71(1), 5-32. <https://doi.org/10.1002/art.40726>

Skyrizi (risankizumab-rzaa) [package insert]. North Chicago, IL: AbbVie Inc.; June 2024. https://www.rxabbvie.com/pdf/skyrizi_pi.pdf

Sotyktu (deucravacitinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb; September 2022. https://packageinserts.bms.com/pi/pi_sotyktu.pdf

Spevigo (spesolimab-sbzo) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; March 2024. <https://content.boehringer-ingelheim.com/DAM/18918a08-b1a0-44f0-8f01-af1e01236719/spevigo-us-pi.pdf>

Stelara (ustekinumab) [package insert]. Horsham, PA: Janssen Biotech August 2022. <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf>

Steqeyma (ustekinumab-stba) [package insert]. Jersey City, NJ: CELLTRION USA, Inc; December 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761338s000lbl.pdf

Taltz (ixekizumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2022. <http://uspl.lilly.com/taltz/taltz.html#pi>

Tofidence (tocilizumab-bavi) [package insert]. Cambridge, MA: Biogen MA Inc; July 2024. <https://www.biogencdn.com/us/biosimilars/biib800-pi.pdf>

Tremfya (guselkumab) [package insert]. Horsham, PA: Janssen Biotech; March 2025. <http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf>

Tyenne (tocilizumab-aazg) [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; February 2025. <https://www.tyenne.com/Tyenne-PI.pdf>

Uplizna (inebilizumab-cdon) [package insert]. Gaithersburg, MD: Viela Bio, Inc; ~~April~~ July 2025[†]. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/uplizna/uplizna_fpi_english.pdf

~~<https://www.hzndocs.com/Uplizna-Prescribing-Information.pdf>~~

Velsipity (etrasimod) [package insert]. New York, NY: Pfizer Inc; November 2023. <https://labeling.pfizer.com/ShowLabeling.aspx?id=19776>

Ward, M, et al. (2015). American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Care and Research*, 68(2), 151-166. <https://doi.org/10.1002/acr.22708>

Wu, J. (2017). Contemporary Management of Moderate to Severe Plaque Psoriasis. *American Journal of Managed Care*, 23, S403-S416. <https://www.ajmc.com/view/contemporary-management-of-moderate-to-severe-plaque-psoriasis>

Xeljanz oral solution, Xeljanz tablet and Xeljanz XR (tofacitinib) [package insert]. New York, NY; Pfizer Labs; December 2021. <labeling.pfizer.com/ShowLabeling.aspx?id=959>

Yesintek (ustekinumab-kfce) [package insert]. Cambridge, MA: Biocon Biologics Inc; November 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761406s000lbl.pdf

Yuflyma (adalimumab-aaty) [package insert]. Jersey City, NJ: CELLTRION USA, Inc; December 2023. <https://www.celltrionusa.com/data/file/product/Yuflyma%20USPI.pdf>

Yusimry (adalimumab-aqvh) [package insert]. Redwood City, CA: Coherus BioSciences, Inc; September 2023. https://assets.website-files.com/6483738bedd883892f331b8d/649b9de6f7a9929ae8e05dca_PI_PMD-0051_R02_V05_FDA.pdf

Zouboulis C, et al. European S1 Guideline for the Treatment of Hidradenitis Suppurativa/Acne Inversa. Journal of European Academy of Dermatology and Venereology. 2015 Apr. 29 (4):619-44. <https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.12966>

Zymfentra (Infliximab-dyyb) [package insert]. Jersey City, NJ: CELLTRION USA, Inc; February 2024. https://zymfentra.b-cdn.net/zymfentra_prescribing_information_final.pdf

Revision / Date	Implementation Date
Removed diagnosis requirement at POS, add non-radiographic axial spondyloarthritis for Cimzia®, add max dose for Actemra® for RA, add severity to RA criteria / May 2019	August 2019
Incorporated Otezla® new indication for oral ulcers associated with Behçet’s Disease, modify age for ulcerative colitis for Inflectra® and Renflexis® / August 2019	November 2019
Added Stelara® to ulcerative colitis (new indication) and Taltz® to Ankylosing Spondylitis (new indication), added specialists to giant cell arteritis, oral ulcers with Bechet’s disease and TRAPS, HIDS, MKD and FMF / January 2020	May 2020
Combined Skyrizi® criteria with Cytokine and CAM Antagonists criteria, formatting changes / July 2020	July 2020
Modified age for Taltz® for plaque psoriasis, added diagnosis of non-radiographic axial spondyloarthritis to Cosentyx® and Taltz®, added diagnosis of Still’s Disease for Ilaris®, clarified diagnosis for Actemra®, updated references, formatting changes / June 2020	October 2020
Modified age for Stelara® for plaque psoriasis, added indication of active psoriatic arthritis to Tremfya®; updated references; incorporated Skyrizi® into the document / September 2020	January 2021
Modified age to Simponi Aria® for active psoriatic arthritis, added indication of polyarticular juvenile idiopathic arthritis; updated reference / September 2020	April 2021
Incorporated new formulation of Xeljanz® oral solution, added indication of polyarticular juvenile idiopathic arthritis; modified age for Simponi Aria®; formatting changes, updated references / November 2020	April 2021
Added Deficiency of Interleukin-1 Receptor Antagonist (DIRA) to Kineret® and Arcalyst®, updated references / January 2021	July 2021
Added Avsola®, Enspryng® and Uplizna®; updated age for Humira®, updated references / February 2021	July 2021
Added Recurrent Pericarditis to Arcalyst®, updated references / March 2021	July 2021
Added Systemic Sclerosis-Associated Interstitial Lung Disease for Actemra®, updated reference / March 2021	July 2021
Updated Cosentyx® age for plaque psoriasis, updated references / June 2021	January 2022
Updated criteria for Rinvoq® and all Xeljanz® formulations to include treatment failure with one or more TNF antagonist, added Rinvoq® to psoriatic arthritis (new indication) and Xeljanz® to	April 2022

ankylosing spondylitis (new indication), updated references / December 2021	
Added indication of prophylaxis for acute graft vs host disease for Orencia®, updated references / December 2021	April 2022
Added indication of atopic dermatitis for Rinvoq®, modified wording for Otezla® to include all adults with plaque psoriasis, added indication of psoriatic arthritis for Skyrizi®, updated age indication of psoriatic arthritis for Cosentyx®, added indication of enthesitis-related arthritis for Cosentyx®, added quantity limits for Humira® and Enbrel®, added COVID-19 statement about Olumiant®, updated references/ February 2022	July 2022
Moved Olumiant COVID-19 statement to criteria, added indication of ulcerative colitis and ankylosing spondylitis for Rinvoq®, added indication of Crohn’s disease for Skyrizi®, removed prescriber attestations regarding Hepatitis B and TB testing, updated references / April 2022	October 2022
Added indication of alopecia areata for Olumiant®, updated psoriatic arthritis age indication for Stelara®, combined Cibinqo™ criteria with Cytokine and CAM Antagonists criteria, updated references / November 2022	January 2023
Added indication of Non-Radiographic Axial Spondyloarthritis for Rinvoq®, updated references / October 2022	April 2023
Combined Amjevita™, Sotyktu™, and Spevigo® with Cytokine and CAM Antagonists criteria, added indication of polymyalgia rheumatica (PMR) for Kevzara®, added ‘preferred alternative’ statement, updated references / December 2022	July 2023
Added indication of Crohn’s disease for Rinvoq®, updated references / May 2023	October 2023
Added indication of uveitis for Amjevita™, removed previous use of a conventional treatment or oral DMARD for Crohn’s disease, Hidradenitis Suppurativa, Psoriatic Arthritis, and Ulcerative Colitis, added Actemra® to COVID-19 statement, combined Cyltezo®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Yuflyma® and Yusimry™, formatting changes, updated references / July 2023	January 2024
Added indications of hidradenitis suppurativa and uveitis for Idacio®, expanded age indication of psoriatic arthritis for Enbrel® and Orencia®, added indication of gout flares for Ilaris®, added indication of hidradenitis suppurativa for Cosentyx®, updated references / November 2023	April 2024
Added indication of uveitis for Yuflyma® and Yusimry™, removed BSA requirement from Otezla®, modified quantity limit criteria for select adalimumab products to reflect new dosage forms, combined Abrilada™, Bimzelx®, Omvoh™ and Velsipity™ with Cytokine and CAM Antagonists criteria, removed QL for Enbrel® and Humira® from criteria, expanded prescriber specialties for select agents, updated references, formatting changes / February 2024	July 2024

Expanded age indication of GPP for Spevigo®, differentiated the use of dosage forms of Spevigo® for GPP, expanded age indication of plaque psoriasis for Otezla®, updated references / April 2024	October 2024
Expanded age indication of psoriatic arthritis for Rinvoq®, added indication of polyarticular juvenile idiopathic arthritis for Kevzara® and Rinvoq®, added Rinvoq® LQ dosage form, added indication of ulcerative colitis for Skyrizi®, added Litfulo™, Simlandi®, Tofidence™, Tyenne®, and Zymfentra™, updated references / August 2024	January 2025
Added indication of polyarticular juvenile idiopathic arthritis for Cimzia®, added indication of ulcerative colitis for Tremfya®, added indications of psoriatic arthritis and ankylosing spondylitis (including non-radiographic axial spondyloarthritis) and Hidradenitis Suppurativa for Bimzelx®, updated references / November 2024	March 2025
Added indication of Crohn's disease for Omvoh™, updated references / January 2025	June 2025
Combined Yesintek™ with criteria document / May 2025	July 2025
Added indication of CRS and COVID-19 for Tyenne®, added indication of Crohn's disease for Tremfya®, added Otulfi™, Pyzchiva®, Selarsdi™, Steqeyma®, updated references / March 2025	August 2025
<u>Added indication of IgG4-RD for Uplizna®, removed the previous use of MTX when Rinvoq® is being used to treat RA, added indication of giant cell arteritis for Rinvoq®, removed previous use of corticosteroids for giant cell arteritis, added criterion requiring the use of Stelara® biosimilars, added quantity limits for selected agents, updated references / June 2025</u>	<u>January 2026</u>